Dr. Sean Tucker, Ph.D
Senior Vice President and Chief Scientific Officer
Dr. Sean Tucker is the Founder of Vaxart and has served as its Chief Scientific Officer since February 2010. From March 2004 to February 2010, Sean served as Vice President of Research and Director of Immunology. He has held numerous scientific and engineering roles at various biotechnology companies.
Sean has a BSc. in chemical engineering from the University of Washington, an MSc. in chemical engineering from the University of California, Berkeley, and a Ph.D. in immunology from the University of Washington.
Rajesh Kapoor, Ph.D
Senior Vice-President for Quality
Rajesh Kapoor has a career spanning thirty years working in the US and internationally with small and large companies covering aseptic and non-aseptic Quality Operations encompassing vaccines, biologics, drugs, APIs, clinical Quality Assurance and radiopharmaceuticals.
Rajesh has played a lead role in successfully bringing pharmaceutical companies into compliance to ensure sustainable commercial product viability. He has been the lead host for many companies to manage Regulatory Agency inspections, providing direct oversight and address questions arising from inspections and CMC sections of product filings. Rajesh has also provided oversight for CMO and CROs with respect to external QA/QC and directly engaged in establishing Quality programs for clinical trials covering the selection of Principle Investigators, training, protocol reviews, approving exception reports, establishing blinded study protocols and direct Quality oversight of Regulatory inspections of domestic and foreign clinical sites.
Rajesh has played a lead Quality role in the successful Regulatory approval and subsequent commercialization of key products, including Rotavirus, Abraxane, Ramelteon and Rifaxamin.
Rajesh holds a Ph.D. in biochemistry from the University of Lancaster, United Kingdom, and an MBA in business administration from Suffolk University, Boston.
Shaily Jaini Garg
Senior Vice-President of Clinical Development
and Project Management
Shaily Jaini Garg has more than twenty-five years’ experience in pharmaceutical drug development, including at Genentech, Oculex and Cerimon where she held roles of increasing responsibility within Regulatory Affairs, Clinical Development and Program Management. Shaily has a wide range of experience working on early- to late-stage clinical programs spanning various indications including infectious diseases and vaccines, oncology, ophthalmology, GI and pain.
Shaily holds a BS in biochemistry from University of California, Davis.
Senior Vice-President for Business Operations
Brant Biehn is responsible for Business Development and Commercial Readiness of the organization.
Prior to joining Vaxart, Brant served as a consultant in business development, investor relations and general management services for a range of pharmaceutical and medical device companies. Before that he served as chief commercial officer at Dynavax Technologies Corporation, where he helped raise significant capital and was responsible for the development and execution of Dynavax’s commercial strategy. This included global sales, marketing and supply chain management and leading a team of 70 professionals preparing to launch Heplisav®.
Brant has held sales and marketing positions of increasing seniority at Merck, culminating in the position of Global Brand Leader with global responsibility for the manufacturing, commercial, clinical and regulatory activities for vaccines such as ZOSTAVAX®, PNEUMOVAX®, RECOMBIVAX HB® and VAQTA®.
Brant has a BSc. in Computer Science from Memorial University of Newfoundland, Canada.
Dr. James F. Cummings
Chief Medical Officer
James Cummings is a Board-Certified Infectious Diseases Physician with a twenty six-year career in the US Army and a proven track record in vaccine, drug and diagnostics development.
James served as Director of the Department of Defense’s Global Emerging Infectious Surveillance and Response System (GEIS), with Bio-surveillance Laboratories in 71 countries, the Director of Translational Medicine & Regulated Activities for the Walter Reed Army Institute of Research (WRAIR), and the Consultant to the Surgeon General for all medical research and development.
Before joining Vaxart, James served as President, Government and Public Health Solutions at ICON GPHS and Vice-President of Clinical Development and Translational Medicine at Novavax.
James has a medical degree from Georgetown University School of Medicine.
Edward B. Berg
Senior Vice President and General Counsel
Mr. Berg has served in senior legal positions at prominent healthcare companies for most of his more than 30-year career and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. Prior to Vaxart, he served as VP, Deputy General Counsel for BioMarin Pharmaceutical Inc. Mr. Berg previously served as VP Legal and the head attorney supporting Novartis’ biosimilar / complex generic unit, the BioPharm division of Sandoz US. Mr. Berg’s previous roles include Deputy General Counsel, Pharmaceutical Operations for Sanofi-Aventis U.S. and Sanofi NA Pharmaceuticals, and Senior Corporate Counsel, Research & Development, Bristol-Myers Squibb, Inc. He began his career in healthcare as Senior Attorney / Associate Counsel for Merck & Co, Inc. Mr. Berg received a B.A. from Washington University in economics and political science and a law degree from the University of Pennsylvania Law School.
Raymond D. Stapleton, Jr., Ph.D.
Chief Technology Officer
Dr. Stapleton served as CTO and Executive Vice President at Genocea, working to develop next generation personalized immunotherapies in the forms of vaccines and cell therapies. He joined Genocea in January 2021, bringing more than 20 years of industry experience to the company, having led technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies.
Before that, he served as President and Chief Operating Officer of American Type Culture Collection (ATCC), as well as a member of the Board of Directors of both ATCC and ATCC Global.
Prior to ATCC, Dr. Stapleton worked in senior manufacturing and technical operations roles at Iovance Biotherapeutics, Inc. and Synthetic Biologics, Inc. after spending 15 years in positions of increasing responsibility in Merck and Company’s manufacturing organization.
At Merck, Dr. Stapleton led a complex science, technology, and engineering organization at a manufacturing site responsible for supporting Merck’s $5 billion annual revenue vaccine business.
Dr. Stapleton earned a bachelor’s degree in Biology from Mary Washington College in Fredericksburg, Virginia and received his PhD in Microbial Ecology from the University of Tennessee, Knoxville. He has served as peer reviewer for a half dozen scientific journals, co-authored 17 peer-reviewed manuscripts, and holds multiple patents.